Search company, investor...

Immunovative Therapies

immunovative.co.il

Founded Year

2004

Stage

Other Investors | Alive

About Immunovative Therapies

Immunovative Therapies, Ltd. (ITL) is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator , a member of the world renown Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist.

Headquarters Location

P.O. Box 974

60850,

Israel

Missing: Immunovative Therapies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Immunovative Therapies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Immunovative Therapies Patents

Immunovative Therapies has filed 1 patent.

The 3 most popular patent topics include:

  • Immunology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2016

1/4/2022

Immunology, Clusters of differentiation, Immune system, Oncology, Transcription factors

Grant

Application Date

1/21/2016

Grant Date

1/4/2022

Title

Related Topics

Immunology, Clusters of differentiation, Immune system, Oncology, Transcription factors

Status

Grant

Latest Immunovative Therapies News

Immunovative Therapies and Mirror Biologics Announce US FDA Clearance of a Universal Anti-Viral Vaccine Phase I/II Clinical Trial for Healthy Elderly Adults

Jun 23, 2020

English News provided by Share this article JERUSALEM and PHOENIX, June 23, 2020 /PRNewswire/ -- Mirror Biologics, Inc. (Phoenix, AZ), the commercial development arm of Immunovative Therapies, Ltd. (Jerusalem, IL) (together "the Company"), a clinical-stage company specialized in the development, manufacturing and clinical translation of next-generation immunotherapy drugs where the active ingredients are living immune cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared our Phase I/II universal virus vaccine clinical trial under the Company's second active Investigational New Drug (IND) application enabling use of the Company's lead experimental drug, AlloStim®, for testing as an anti-viral prophylaxis drug. AlloStim® is an off-the-shelf, non-genetically manipulated, patented living immune cell with multiple immunodulatory properties, currently being tested under a separate IND as a therapeutic vaccine for chemotherapy-refractory metastatic cancers. This Phase I/II trial is believed to be the first anti-viral vaccine in clinical development that is specifically targeted to protect the elderly. The elderly are the most vulnerable in our society to the severe and lethal effects of respiratory viral infections which cause disease complications such as pneumonia. Pneumonia is the single most common cause of death from infectious disease in those over 65 years old. The chance that a COVID-19 patient will develop symptoms severe enough to require hospitalization and  respiratory support rises sharply with age and the death rate due to COVID-19 is disproportionately higher in our senior citizens. Dr. Michael Har-Noy, founder and CEO stated: "We are pleased to have FDA clearance of our novel universal viral vaccine clinical trial targeted to healthy adults over 65 years old. There is a large unmet need to protect the elderly from the devastating effects of respiratory viral infection. If we can protect the elderly from COVID-19, economies can open safely and herd immunity can be allowed to develop without an alarming increase in death rate. Even if a COVID-19 vaccine is developed, it is likely, as with influenza vaccines, that it will be less effective in the elderly where protection is most needed. In addition, a successful COVID-19 vaccine is vulnerable to weakening upon mutation of the virus and will not protect against future novel viral outbreaks. Our universal vaccine technology is designed to protect against any type of viral infection without the requirement to have prior knowledge of the viral structure and is specifically designed to work in the weakened senescent immune systems of the elderly and frail." The Phase I/II clinical trial will accrue 40 healthy adults over age 65. Volunteers will receive five (5) intradermal injections of AlloStim® over 14 days. Blood samples will be collected prior to injection and at 30 days, 6 months and 1 year after injection. The blood will be challenged in the laboratory with a panel of live viruses, including the COVID-19 virus and influenza viruses in order to determine if the remodeled immune system can suppress the propagation of these viruses in cultures of human endothelial cells from the respiratory tract. Details of the clinical trial can be found on the National Institutes of Health ClinicalTrials.gov registry: ClinicalTrials.gov Identifier: NCT04441047 The universal viral protection mechanism has been reversed engineered from the immune response that results in asymptomatic viral clearance in youthful individuals. Using a novel, patent-pending technology called "allo-priming", the youthful immune response is imprinted upon the elderly immune system so that it can be ready to be activated upon encounter with any virus. The mechanism creates conditions for an "in-situ" vaccine providing viral-specific protection and memory to prevent re-infection from the same virus. The novel mechanism has been described in a peer-reviewed article published in the Journal of Translational Medicine which can be viewed by following this link . AlloStim® is derived from precursor cells purified from the blood of healthy donors. The Company will be working to scale up and automate the production process in parallel with on-going clinical trials so that upon demonstration of safety and efficacy, the vaccine can be quickly scaled-up to quantities necessary to protect the elderly population. Today, there is estimated to be more than 46 million adults age 65 and older living in the USA. Media Contact:

Immunovative Therapies Frequently Asked Questions (FAQ)

  • When was Immunovative Therapies founded?

    Immunovative Therapies was founded in 2004.

  • What is Immunovative Therapies's latest funding round?

    Immunovative Therapies's latest funding round is Other Investors.

  • Who are the investors of Immunovative Therapies?

    Investors of Immunovative Therapies include Misgav Venture Accelerator and The Trendlines Group.

  • Who are Immunovative Therapies's competitors?

    Competitors of Immunovative Therapies include Quantum Leap Innovations, ForSight VISION4, Catalyst Biosciences, TheraVasc, Maxygen and 11 more.

Compare Immunovative Therapies to Competitors

Bio-Link Logo
Bio-Link

Bio-Link is a National Advanced Technological Education (ATE) Center for Biotechnology that originated in late 1998 with a grant from the National Science Foundation. The ATE program was created to improve and expand educational programs that prepare skilled technicians to work in the high-tech fields that drive the U.S. economy. Bio-Link enhances and expands biotechnology education programs by providing professional development for instructors, by improving curriculum, by making use of technologies and by creating a system that promotes the sharing of information. The Bio-Link National Center is at City College of San Francisco with office space at the University of California San Francisco. Regional Bio-Link Centers across the country are located in Seattle, WA; San Diego, CA; San Francisco, CA; Austin, TX; Madison, WI; Graham, NC; and Portsmouth, NH. The regional centers develop relations with local industry and educational institutions including community colleges, baccalaureate institutions, and high schools. In addition, each regional center spearheads a different element of the program. Bio-Link is supporting a cadre of well-trained instructors and is increasing the number and quality of biotechnology programs for students. Bio-Link aiming to bring a range of underrepresented students to biotechnology who have the knowledge and skills essential to the field as well as the ability to continue with more advanced education in math, science and engineering. At a press conference, on October 15th, 1998, at City College of San Francisco (CCSF), Chancellor Philip R. Day, Jr. stated, "Bio-Link represents a opportunity for community colleges to take a lead in technical training and retraining for the skilled biotechnology workforce of the twenty-first century."nnDr. Elaine Johnson, Director of the National Center and faculty member of CCSF remarked, "In making this award, NSF recognizes both the importance of creating a high performance technical workforce for a competitive global economy and the critical role community and technical colleges play in the education of technicians."

Biolog Logo
Biolog

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

V
VidaGene

VidaGene,Inc., is a biopharmaceutical company that aims to develop pharmaceuticals based on modulation of the vitamin D receptor (VDR). VidaGene seeks to develop entirely new VDR modulators for large pharmaceutical markets such as cancer-related thrombosis, osteoporosis and psoriasis.

P
Protherics plc

Protherics is an international biopharmaceutical company focused on specialist products for critical care and cancer.nThe Company has two critical care products, CroFab and DigiFab, approved for sale in the US. The Company has the opportunity to sell these products in the US from October 2010 together with Voraxaze, a supportive cancer care product, following anticipated approval in the US in 2010. Protherics is also developing a number of other products in the cancer arena that it can commercialise in-house.nIn addition, Protherics has several potential blockbuster products that require development and commercialisation partners. These include CytoFab which has been partnered by AstraZeneca in a major licensing deal, and also Angiotensin Therapeutic Vaccine and Digoxin Immune Fabs for which licensing partners will be sought in 2008-2009. These products have the potential to be high value products that can provide additional funding for the Company.n

Q
Qyntessa Biologics

Qyntessa Biologics aims to provide clinical manufacturing, (cGMP biologics manufacturing), process development, cell banking, cell line development, testing and fill/finish for researchers and biopharmaceutical companies who do not have the facilities and competencies for clinical manufacturing.

T
TargAnox

TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.